Literature DB >> 26253079

What to do about pertussis vaccines? Linking what we know about pertussis vaccine effectiveness, immunology and disease transmission to create a better vaccine.

Shelly Bolotin1, Eric T Harvill2, Natasha S Crowcroft3.   

Abstract

Pertussis (whooping cough) is a respiratory disease caused by the bacterium Bordetella pertussis. Despite the implementation of immunization programs and high vaccine coverage in most jurisdictions, pertussis is still one of the most common vaccine-preventable diseases, suggesting that the current vaccines and immunization schedules have not been sufficiently effective. Several factors are thought to contribute to this. The acellular pertussis vaccine that has been used in many jurisdictions since the 1990s is less effective than the previously used whole-cell vaccine, with immunity waning over time. Both whole-cell and acellular pertussis vaccines are effective at reducing disease severity but not transmission, resulting in outbreaks in vaccinated cohorts. In this review, we discuss various limitations of the current approaches to protection from pertussis and outline various options for reducing the burden of pertussis on a population level. © Published by Oxford University Press on behalf of FEMS 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US.

Entities:  

Keywords:  Pertussis; immunity; transmission; vaccine; vaccine effectiveness; whooping cough

Mesh:

Substances:

Year:  2015        PMID: 26253079      PMCID: PMC4626586          DOI: 10.1093/femspd/ftv057

Source DB:  PubMed          Journal:  Pathog Dis        ISSN: 2049-632X            Impact factor:   3.166


  63 in total

Review 1.  How to make sense of pertussis immunogenicity data.

Authors:  P Olin; H O Hallander; L Gustafsson; E Reizenstein; J Storsaeter
Journal:  Clin Infect Dis       Date:  2001-12-15       Impact factor: 9.079

Review 2.  Control of adaptive immune responses by Toll-like receptors.

Authors:  Gregory M Barton; Ruslan Medzhitov
Journal:  Curr Opin Immunol       Date:  2002-06       Impact factor: 7.486

3.  Phase II trial of whole-cell pertussis vaccine vs an acellular vaccine containing agglutinogens.

Authors:  E Miller; L A Ashworth; A Robinson; P A Waight; L I Irons
Journal:  Lancet       Date:  1991-01-12       Impact factor: 79.321

4.  Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children.

Authors:  M Ryan; G Murphy; E Ryan; L Nilsson; F Shackley; L Gothefors; K Oymar; E Miller; J Storsaeter; K H Mills
Journal:  Immunology       Date:  1998-01       Impact factor: 7.397

Review 5.  Adult pertussis: a salesman's dream--and an epidemiologist's nightmare.

Authors:  P E Fine
Journal:  Biologicals       Date:  1997-06       Impact factor: 1.856

6.  The recurrence of whooping cough: possible implications for assessment of vaccine efficacy.

Authors:  P E Fine; J A Clarkson
Journal:  Lancet       Date:  1982-03-20       Impact factor: 79.321

Review 7.  Reflections on the efficacy of pertussis vaccines.

Authors:  P E Fine; J A Clarkson
Journal:  Rev Infect Dis       Date:  1987 Sep-Oct

8.  The changing age and seasonal profile of pertussis in Canada.

Authors:  Danuta M Skowronski; Gaston De Serres; Diane MacDonald; Wrency Wu; Carol Shaw; Jane Macnabb; Sylvie Champagne; David M Patrick; Scott A Halperin
Journal:  J Infect Dis       Date:  2002-04-22       Impact factor: 5.226

9.  Trends in pertussis among infants in the United States, 1980-1999.

Authors:  Masahiro Tanaka; Charles R Vitek; F Brian Pascual; Kristine M Bisgard; Jacqueline E Tate; Trudy V Murphy
Journal:  JAMA       Date:  2003-12-10       Impact factor: 56.272

10.  Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine.

Authors:  A Podda; G Bona; G Canciani; A M Pistilli; B Contu; R Furlan; T Meloni; D Stramare; L Titone; R Rappuoli
Journal:  J Pediatr       Date:  1995-08       Impact factor: 4.406

View more
  9 in total

Review 1.  Bordetella pertussis: new concepts in pathogenesis and treatment.

Authors:  Nicholas H Carbonetti
Journal:  Curr Opin Infect Dis       Date:  2016-06       Impact factor: 4.915

Review 2.  Pneumococcal whole-cell and protein-based vaccines: changing the paradigm.

Authors:  Michael E Pichichero
Journal:  Expert Rev Vaccines       Date:  2017-12       Impact factor: 5.217

Review 3.  What Is Wrong with Pertussis Vaccine Immunity? The Problem of Waning Effectiveness of Pertussis Vaccines.

Authors:  Nicolas Burdin; Lori Kestenbaum Handy; Stanley A Plotkin
Journal:  Cold Spring Harb Perspect Biol       Date:  2017-12-01       Impact factor: 10.005

4.  Development and validation of a robust multiplex serological assay to quantify antibodies specific to pertussis antigens.

Authors:  Gowrisankar Rajam; George Carlone; Ellie Kim; Jin Choi; Simon Paulos; SoHee Park; Amilia Jeyachandran; Yamini Gorantla; Emily Wong; Amit Sabnis; Peter Browning; Rita Desai; Conrad P Quinn; Jarad Schiffer
Journal:  Biologicals       Date:  2018-11-18       Impact factor: 1.856

5.  Does the economic recession influence the incidence of pertussis in a cosmopolitan European city?

Authors:  Sílvia Brugueras; Cristina Rius; Joan-Pau Millet; Martí Casals; Joan A Caylà
Journal:  BMC Public Health       Date:  2019-02-04       Impact factor: 3.295

6.  Clinical and epidemiological characteristics of whooping cough in hospitalized patients of a tertiary care hospital in Peru.

Authors:  Pamela Yesquen; Eder Herrera-Perez; Raffo Escalante-Kanashiro
Journal:  Rev Bras Ter Intensiva       Date:  2019-05-23

7.  Use of a 40-day rolling incidence to monitor pertussis in Nova Scotia, 2015.

Authors:  B Born; A Coombs; V Ryan; M LaFreniere; L Earle; S Fleming; A Fitzgerald; F Atherton
Journal:  Can Commun Dis Rep       Date:  2017-02-02

8.  Whole-Cell or Acellular Pertussis Primary Immunizations in Infancy Determines Adolescent Cellular Immune Profiles.

Authors:  Saskia van der Lee; Lotte H Hendrikx; Elisabeth A M Sanders; Guy A M Berbers; Anne-Marie Buisman
Journal:  Front Immunol       Date:  2018-01-24       Impact factor: 7.561

9.  Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study.

Authors:  Martina Kovac; Lusiné Kostanyan; Narcisa Mesaros; Sherine Kuriyakose; Meera Varman
Journal:  Hum Vaccin Immunother       Date:  2018-05-10       Impact factor: 3.452

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.